Pharmacodynamics of ceftolozane plus tazobactam studied in an In Vitro pharmacokinetic model of infection

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 515-521

  MacGowan, Alasdair P ^a   Noel, Alan R ^a   Tomaselli, Sharon G ^a   Nicholls, Donna ^a   Bowker, Karen E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; TAZOBACTAM; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE CTX-M-15; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; OPRD PROTEIN, PSEUDOMONAS AERUGINOSA; PENICILLANIC ACID; PORIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG HALF LIFE; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; BACTERIAL COUNT; BIOREACTOR; COMPUTER SIMULATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HALF LIFE TIME; INFUSION PUMP; METABOLISM; MICROBIAL SENSITIVITY TEST; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BIOREACTORS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; ESCHERICHIA COLI; GENE EXPRESSION; HALF-LIFE; INFUSION PUMPS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PENICILLANIC ACID; PORINS; PSEUDOMONAS AERUGINOSA;

EID: 84957928059     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00727-15     Document Type: Article

References (24)

1. Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin J. 2013 A multicenter, double-blind, randomized, phase 2 study to assess the safety and efficacy of ceftolozane/tazobactam (TOL/TAZ) plus metronidazole (MTZ) compared with meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI), abstr K-1709. 53rd Intersci Conf Antimicrob Agents Chemother.
2. ClinicalTrials.gov. 2010. Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients with Complicated Urinary Tract Infections, study NCT00921024. www.clinicaltrials.gov.
3. Farrell DJ, Sader HS, Flamm RK, Jones RN. 2014. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centers (2012). Int J Antimicrob Agents 43:533-539. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.032.
4. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
5. Jones RN, Mendes R, Sader HS. 2010. Ceftolozane activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 65(Suppl 4):iv17-iv31. http://dx.doi.org/10.1093/jac/dkq252.
6. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. 2014. Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae, Pseudomonas aeruginosa with various resistance patterns isolated in European hospitals. J Antimicrob Chemother 69:2713-2722. http://dx.doi.org/10.1093/jac/dku184.
7. Giske CG, Ge J, Nordmann P. 2009. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended spectrum β-lactamase producing Pseudomonas aeruginosa. J Antimicrob Chemother 64:430-431. http://dx.doi.org/10.1093/jac/dkp193.
8. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multi-drug resistance. Antimicrob Agents Chemother 54:557-559. http://dx.doi.org/10.1128/AAC.00912-09.
9. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
10. MacGowan AP, Bowker KE, Noel AR. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023 in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrobial Agents Chemother 52:1401-1406. http://dx.doi.org/10.1128/AAC.01153-07.
11. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101 - a new anti-pseudomonal cephalosporin, in healthy adult male and female subjects receiving single and multiple dose intravenous infusions. Antimicrob Agents Chemother 54:3427-3431. http://dx.doi.org/10.1128/AAC.01753-09.
12. Sorgel F, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31(Suppl A):39-60.
13. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed, MO7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. 1988. Correlation of antimicrobial pharmacokinetic parameters and therapeutic efficacy in an animal model. J Infect Dis 158:831-847. http://dx.doi.org/10.1093/infdis/158.4.831.
15. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479-501. http://dx.doi.org/10.1016/S0891-5520(03)00065-5.
16. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
17. MacGowan AP, Noel AR, Tomaselli S, Elliott H, Bowker KE. 2011. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:1436-1442. http://dx.doi.org/10.1128/AAC.00936-10.
18. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. 2014. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 58:6311-6314. http://dx.doi.org/10.1128/AAC.03572-14.
19. Bowker KE, Noel AR, Tomaselli SE, Nicholls DL, MacGowan AP. 2012. Pharmacodynamics of piperacillin-tazobactam (P/T) against Pseudomonas aeruginosa: antibacterial effect and risk of emergence of resistance, abstr A642. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA. American Society for Microbiology, Washington, DC.
20. VanScoy B, Mendes RE, Nicasio AM, Castanheia M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PM. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.
21. Bowker KE, Noel AR, Tomaselli SE, Nicholls DL, MacGowan AP. Pharmacodynamics of ceftaroline against Enterobacteriaceae, abstr A629. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA. American Society for Microbiology, Washington, DC.
22. Bowker KE, Noel AR, Tomaselli SE, Elliott H, MacGowan AP. 2012. Pharmacodynamics of the antibacterial effect and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumanii in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 56:5009. http://dx.doi.org/10.1128/AAC.06111-11.
23. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vitro comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 56:544-549. http://dx.doi.org/10.1128/AAC.01752-10.
24. MacGowan AP, Rogers CA, Holt HA, Bowker KE. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumonia and Pseudomonas aeruginosa in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 47:1088-1095. http://dx.doi.org/10.1128/AAC.47.3.1088-1095.2003.